Abstract
Vascular liver disease may affect the portal vein, the sinusoids, or the hepatic veins, and may be congenital or develop later during childhood. Clinical presentations vary markedly, depending on the location of the disease in the hepatic vascular anatomy, the nature of the pathology, the degree of hemodynamic change, and the acuity of onset of any vascular obstruction. Affected children may develop clinical manifestations of portal hypertension (e.g., ascites, gastrointestinal bleeding), portosystemic shunting (e.g., encephalopathy, hepatopulmonary syndrome), liver failure, liver masses, or high-output heart failure. Accurate diagnosis depends mostly on imaging. Treatments are directed at specific pathologies and hemodynamic abnormalities, and include medical therapies (e.g., nonspecific beta-blockers, defibrotide), interventional radiology procedures, and surgery. We describe the current approach to children with portal vein thrombosis, Budd-Chiari syndrome, sinusoidal obstruction syndrome, idiopathic non-cirrhotic portal hypertension, congenital vascular malformations, and liver vascular tumors.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Suchy FJ, Sokol RJ, Balistreri WF. Liver disease in children. 3rd ed. Cambridge: Cambridge University Press; 2007, xvii, 1030 p, 22 p, of plates p.
Collardeau-Frachon S, Scoazec JY. Vascular development and differentiation during human liver organogenesis. Anat Rec (Hoboken). 2008;291(6):614–27.
Sherlock S, Dooley J. Diseases of the liver and biliary system. 11th ed. Malden: Blackwell Science; 2002, xvi, 706 p.
Valla DC, Condat B. Portal vein thrombosis in adults: pathophysiology, pathogenesis and management. J Hepatol. 2000;32(5):865–71.
Shneider B, Emre S, Groszmann R, Karani J, McKiernan P, Sarin S, et al. Expert pediatric opinion on the report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. Pediatr Transplant. 2006;10(8):893–907.
Sarin SK, Sollano JD, Chawla YK, Amarapurkar D, Hamid S, Hashizume M, et al. Consensus on extra-hepatic portal vein obstruction. Liver Int. 2006;26(5):512–9.
Senzolo M, Riggio O, Primignani M. Vascular disorders of the liver: recommendations from the Italian Association for the Study of the Liver (AISF) ad hoc committee. Dig Liver Dis. 2011;43:503–14.
Shneider BL, Bosch J, de Franchis R, Emre SH, Groszmann RJ, Ling SC, et al. Portal hypertension in children: expert pediatric opinion on the report of the Baveno V Consensus Workshop on Methodology of Diagnosis and Therapy in Portal Hypertension. Pediatr Transplant. 2012;16(5):426–37
Plessier A, Rautou PE, Valla DC. Management of hepatic vascular diseases. J Hepatol. 2012;56 Suppl 1:S25–38.
Garcia-Pagan JC, Hernandez-Guerra M, Bosch J. Extrahepatic portal vein thrombosis. Semin Liver Dis. 2008;28(3):282–92.
Williams S, Chan AK. Neonatal portal vein thrombosis: diagnosis and management. Semin Fetal Neonatal Med. 2011;16:329–39.
Sakha SH, Rafeey M, Tarzamani MK. Portal venous thrombosis after umbilical vein catheterization. Indian J Gastroenterol. 2007;26(6):283–4.
Morag I, Epelman M, Daneman A, Moineddin R, Parvez B, Shechter T, et al. Portal vein thrombosis in the neonate: risk factors, course, and outcome. J Pediatr. 2006;148(6):735–9.
Morag I, Shah PS, Epelman M, Daneman A, Strauss T, Moore AM. Childhood outcomes of neonates diagnosed with portal vein thrombosis. J Paediatr Child Health. 2011;47(6):356–60.
Seixas CA, Hessel G, Siqueira LH, Machado TF, Gallizoni AM, Annichino-Bizzacchi JM. Study of hemostasis in pediatric patients with portal vein thrombosis. Haematologica. 1998;83(10):955–6.
Pinto RB, Silveira TR, Bandinelli E, Rohsig L. Portal vein thrombosis in children and adolescents: the low prevalence of hereditary thrombophilic disorders. J Pediatr Surg. 2004;39(9):1356–61.
Abd El-Hamid N, Taylor RM, Marinello D, Mufti GJ, Patel R, Mieli-Vergani G, et al. Aetiology and management of extrahepatic portal vein obstruction in children: King’s College Hospital experience. J Pediatr Gastroenterol Nutr. 2008;47(5):630–4.
Pietrobattista A, Luciani M, Abraldes JG, Candusso M, Pancotti S, Soldati M, et al. Extrahepatic portal vein thrombosis in children and adolescents: influence of genetic thrombophilic disorders. World J Gastroenterol. 2010;16(48):6123–7.
Heller C, Schobess R, Kurnik K, Junker R, Gunther G, Kreuz W, et al. Abdominal venous thrombosis in neonates and infants: role of prothrombotic risk factors – a multicentre case–control study. For the Childhood Thrombophilia Study Group. Br J Haematol. 2000;111(2):534–9.
El-Karaksy H, El-Koofy N, El-Hawary M, Mostafa A, Aziz M, El-Shabrawi M, et al. Prevalence of factor V Leiden mutation and other hereditary thrombophilic factors in Egyptian children with portal vein thrombosis: results of a single-center case–control study. Ann Hematol. 2004;83(11):712–5.
Mack CL, Superina RA, Whitington PF. Surgical restoration of portal flow corrects procoagulant and anticoagulant deficiencies associated with extrahepatic portal vein thrombosis. J Pediatr. 2003;142(2):197–9.
Odievre M, Pige G, Alagille D. Congenital abnormalities associated with extrahepatic portal hypertension. Arch Dis Child. 1977;52(5):383–5.
Sarin SK, Bansal A, Sasan S, Nigam A. Portal-vein obstruction in children leads to growth retardation. Hepatology. 1992;15(2):229–33.
Mehrotra RN, Bhatia V, Dabadghao P, Yachha SK. Extrahepatic portal vein obstruction in children: anthropometry, growth hormone, and insulin-like growth factor I. J Pediatr Gastroenterol Nutr. 1997;25(5):520–3.
Mack CL, Zelko FA, Lokar J, Superina R, Alonso EM, Blei AT, et al. Surgically restoring portal blood flow to the liver in children with primary extrahepatic portal vein thrombosis improves fluid neurocognitive ability. Pediatrics. 2006;117(3):e405–12.
Alvarez F, Bernard O, Brunelle F, Hadchouel P, Odievre M, Alagille D. Portal obstruction in children. I. Clinical investigation and hemorrhage risk. J Pediatr. 1983;103(5):696–702.
Khuroo MS, Yattoo GN, Zargar SA, Javid G, Dar MY, Khan BA, et al. Biliary abnormalities associated with extrahepatic portal venous obstruction. Hepatology. 1993;17(5):807–13.
Gauthier-Villars M, Franchi S, Gauthier F, Fabre M, Pariente D, Bernard O. Cholestasis in children with portal vein obstruction. J Pediatr. 2005;146(4):568–73.
de Franchis R, Baveno VF. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2010;53(4):762–8.
DeLeve LD, Valla DC, Garcia-Tsao G. Vascular disorders of the liver. Hepatology. 2009;49(5):1729–64.
Superina R, Bambini DA, Lokar J, Rigsby C, Whitington PF. Correction of extrahepatic portal vein thrombosis by the mesenteric to left portal vein bypass. Ann Surg. 2006;243(4):515–21.
Superina R, Shneider B, Emre S, Sarin S, de Ville de Goyet J. Surgical guidelines for the management of extra-hepatic portal vein obstruction. Pediatr Transplant. 2006;10(8):908–13.
Ling SC, Walters T, McKiernan PJ, Schwarz KB, Garcia-Tsao G, Shneider BL. Primary prophylaxis of variceal hemorrhage in children with portal hypertension: a framework for future research. J Pediatr Gastroenterol Nutr. 2011;52(3):254–61.
Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biology of Blood and Marrow. 2010;16(2):157–68.
McDonald GB. Hepatobiliary complications of hematopoietic cell transplantation, 40 years on. Hepatology. 2010;51(4):1450–60.
McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med. 1993;118(4):255–67.
Corbacioglu S, Cesaro S, Faraci M, Valteau-Couanet D, Gruhn B, Rovelli A, et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet. 2012;379(9823):1301–9.
Reiss U, Cowan M, McMillan A, Horn B. Hepatic venoocclusive disease in blood and bone marrow transplantation in children and young adults: incidence, risk factors, and outcome in a cohort of 241 patients. J Pediatr Hematol Oncol. 2002;24(9):746–50.
Corbacioglu S, Honig M, Lahr G, Stohr S, Berry G, Friedrich W, et al. Stem cell transplantation in children with infantile osteopetrosis is associated with a high incidence of VOD, which could be prevented with defibrotide. Bone Marrow Transplant. 2006;38(8):547–53.
Ouachee-Chardin M, Elie C, de Saint Basile G, Le Deist F, Mahlaoui N, Picard C, et al. Hematopoietic stem cell transplantation in hemophagocytic lymphohistiocytosis: a single-center report of 48 patients. Pediatrics. 2006;117(4):e743–50.
Jones RJ, Lee KS, Beschorner WE, Vogel VG, Grochow LB, Braine HG, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation. 1987;44(6):778–83.
Carreras E, Granena A, Navasa M, Bruguera M, Marco V, Sierra J, et al. On the reliability of clinical criteria for the diagnosis of hepatic veno-occlusive disease. Ann Hematol. 1993;66(2):77–80.
Puig N, de la Rubia J, Remigia MJ, Jarque I, Martin G, Cupelli L, et al. Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation. Leuk Lymphoma. 2006;47(8):1488–94.
de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R, et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood. 2004;104(3):857–64.
Tay J, Tinmouth A, Fergusson D, Huebsch L, Allan DS. Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13(2):206–17.
Richardson PG, Murakami C, Jin Z, Warren D, Momtaz P, Hoppensteadt D, et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood. 2002;100(13):4337–43.
Richardson PG, Soiffer RJ, Antin JH, Uno H, Jin Z, Kurtzberg J, et al. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Biol Blood Marrow Transplant. 2010;16(7):1005–17.
DeLeve LD. Vascular liver diseases. Curr Gastroenterol Rep. 2003;5(1):63–70.
Horton JD, San Miguel FL, Membreno F, Wright F, Paima J, Foster P, et al. Budd-Chiari syndrome: illustrated review of current management. Liver Int. 2008;28:455–66.
Hadengue A, Poliquin M, Vilgrain V, Belghiti J, Degott C, Erlinger S, et al. The changing scene of hepatic vein thrombosis: recognition of asymptomatic cases. Gastroenterology. 1994;106(4):1042–7.
Valla DC. Primary Budd-Chiari syndrome. J Hepatol. 2009;50:195–203.
Valla D-C. Hepatic venous outflow tract obstruction etiopathogenesis: Asia versus the West. J Gastroenterol Hepatol. 2004;19:S204–11.
Darwish Murad S, Plessier A, Hernandez-Guerra M, Fabris F, Eapen CE, Bahr MJ, et al. Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med. 2009;151:167–75.
Shetty S, Ghosh K. Thrombophilic dimension of Budd Chiari syndrome and portal venous thrombosis – a concise review. Thromb Res. 2011;127:505–12.
Deltenre P, Denninger MH, Hillaire S, Guillin MC, Casadevall N, Briere J, et al. Factor V Leiden related Budd-Chiari syndrome. Gut. 2001;48(2):264–8.
Nagral A, Hasija RP, Marar S, Nabi F. Budd-Chiari syndrome in children: experience with therapeutic radiological intervention. J Pediatr Gastroenterol Nutr. 2010;50(1):74–8.
Vickers CR, West RJ, Hubscher SG, Elias E. Hepatic vein webs and resistant ascites. Diagnosis, management and implications. J Hepatol. 1989;8(3):287–93.
Kage M, Arakawa M, Kojiro M, Okuda K. Histopathology of membranous obstruction of the inferior vena cava in the Budd-Chiari syndrome. Gastroenterology. 1992;102(6):2081–90.
Gentil-Kocher S, Bernard O, Brunelle F, Hadchouel M, Maillard JN, Valayer J, et al. Budd-Chiari syndrome in children: report of 22 cases. J Pediatr. 1988;113(1 Pt 1):30–8.
MacSween RNM, Anthony PP, Scheuer PJ. Pathology of the liver. Edinburgh/New York: Churchill Livingstone; 1979. p. 458.
Cauchi JA, Oliff S, Baumann U, Mirza D, Kelly DA, Hewitson J, et al. The Budd-Chiari syndrome in children: the spectrum of management. J Pediatr Surg. 2006;41(11):1919–23.
Gomes AC, Rubino G, Pinto C, Cipriano A, Furtado E, Goncalves I. Budd-Chiari syndrome in children and outcome after liver transplant. Pediatr Transplant. 2012;16:E338–41.
Nezakatgoo N, Shokouh-Amiri MH, Gaber AO, Grewal HP, Vera SR, Chamsuddin AA, et al. Liver transplantation for acute Budd-Chiari syndrome in identical twin sisters with factor V leiden mutation. Transplantation. 2003;76(1):195–8.
Odell JA, Rode H, Millar AJ, Hoffman HD. Surgical repair in children with the Budd-Chiari syndrome. J Thorac Cardiovasc Surg. 1995;110(4 Pt 1):916–23.
Dhiman RK, Chawla Y, Vasishta RK, Kakkar N, Dilawari JB, Trehan MS, et al. Non-cirrhotic portal fibrosis (idiopathic portal hypertension): experience with 151 patients and a review of the literature. J Gastroenterol Hepatol. 2002;17:6–16.
Schouten JN, Garcia-Pagan JC, Valla DC, Janssen HL. Idiopathic noncirrhotic portal hypertension. Hepatology. 2011;54(3):1071–81.
Hübscher SG. Pathology of non-cirrhotic portal hypertension and incomplete septal cirrhosis. Diagn Histopathol. 2011;17(12):530–8.
Nakanuma Y, Hoso M, Sasaki M, Terada T, Katayanagi K, Nonomura A, et al. Histopathology of the liver in non-cirrhotic portal hypertension of unknown aetiology. Histopathology. 1996;28(3):195–204.
Hillaire S, Bonte E, Denninger MH, Casadevall N, Cadranel JF, Lebrec D, et al. Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients. Gut. 2002;51(2):275–80.
Sarin SK, Agarwal SR. Extrahepatic portal vein obstruction. Semin Liver Dis. 2002;22(1):43–58.
Yilmaz G, Sari S, Egritas O, Dalgic B, Akyol G. Hepatoportal sclerosis in childhood: some presenting with cholestatic features (a re-evaluation of 12 children). Pediatr Dev Pathol. 2012;15(2):107–13.
Eapen CE, Nightingale P, Hubscher SG, Lane PJ, Plant T, Velissaris D, et al. Non-cirrhotic intrahepatic portal hypertension: associated gut diseases and prognostic factors. Dig Dis Sci. 2011;56(1):227–35.
Seijo S, Reverter E, Miquel R, Berzigotti A, Abraldes JG, Bosch J, et al. Role of hepatic vein catheterisation and transient elastography in the diagnosis of idiopathic portal hypertension. Dig Liver Dis. 2012;44(10):855–60.
Moran CA, Mullick FG, Ishak KG. Nodular regenerative hyperplasia of the liver in children. Am J Surg Pathol. 1991;15(5):449–54.
Abramowsky C, Romero R, Heffron T. Pathology of noncirrhotic portal hypertension: clinicopathologic study in pediatric patients. Pediatr Dev Pathol. 2003;6(5):421–6.
De Bruyne R, Portmann B, Samyn M, Bansal S, Knisely A, Mieli-Vergani G, et al. Chronic liver disease related to 6-thioguanine in children with acute lymphoblastic leukaemia. J Hepatol. 2006;44(2):407–10.
Dabritz J, Worch J, Materna U, Koch B, Koehler G, Duck C, et al. Life-threatening hypersplenism due to idiopathic portal hypertension in early childhood: case report and review of the literature. BMC Gastroenterol. 2010;10:122.
Al-Mukhaizeem KA, Rosenberg A, Sherker AH. Nodular regenerative hyperplasia of the liver: an under-recognized cause of portal hypertension in hematological disorders. Am J Hematol. 2004;75(4):225–30.
Boon LM, Burrows PE, Paltiel HJ, Lund DP, Ezekowitz RA, Folkman J, et al. Hepatic vascular anomalies in infancy: a twenty-seven-year experience. J Pediatr. 1996;129(3):346–54.
Burrows PE, Dubois J, Kassarjian A. Pediatric hepatic vascular anomalies. Pediatr Radiol. 2001;31(8):533–45.
Alexander CP, Sood BG, Zilberman MV, Becker C, Bedard MP. Congenital hepatic arteriovenous malformation: an unusual cause of neonatal persistent pulmonary hypertension. J Perinatol. 2006;26(5):316–8.
Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet. 2000;91(1):66–7.
Faughnan ME, Palda VA, Garcia-Tsao G, Geisthoff UW, McDonald J, Proctor DD, et al. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet. 2011;48(2):73–87.
Garcia-Tsao G. Liver involvement in hereditary hemorrhagic telangiectasia (HHT). J Hepatol. 2007;46(3):499–507.
Buscarini E, Leandro G, Conte D, Danesino C, Daina E, Manfredi G, et al. Natural history and outcome of hepatic vascular malformations in a large cohort of patients with hereditary hemorrhagic teleangiectasia. Dig Dis Sci. 2011;56(7):2166–78.
Memeo M, Stabile Ianora AA, Scardapane A, Suppressa P, Cirulli A, Sabba C, et al. Hereditary haemorrhagic telangiectasia: study of hepatic vascular alterations with multi-detector row helical CT and reconstruction programs. Radiol Med. 2005;109(1–2):125–38.
Buscarini E, Plauchu H, Garcia Tsao G, White Jr RI, Sabba C, Miller F, et al. Liver involvement in hereditary hemorrhagic telangiectasia: consensus recommendations. Liver Int. 2006;26(9):1040–6.
Al-Saleh S, John PR, Letarte M, Faughnan ME, Belik J, Ratjen F. Symptomatic liver involvement in neonatal hereditary hemorrhagic telangiectasia. Pediatrics. 2011;127(6):e1615–20.
Brenard R, Chapaux X, Deltenre P, Henrion J, De Maeght S, Horsmans Y, et al. Large spectrum of liver vascular lesions including high prevalence of focal nodular hyperplasia in patients with hereditary haemorrhagic telangiectasia: the Belgian Registry based on 30 patients. Eur J Gastroenterol Hepatol. 2010;22(10):1253–9.
Garcia-Tsao G, Korzenik JR, Young L, Henderson KJ, Jain D, Byrd B, et al. Liver disease in patients with hereditary hemorrhagic telangiectasia. N Engl J Med. 2000;343(13):931–6.
Dupuis-Girod S, Ginon I, Saurin JC, Marion D, Guillot E, Decullier E, et al. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA. 2012;307(9):948–55.
Mitchell A, Adams LA, MacQuillan G, Tibballs J, vanden Driesen R, Delriviere L. Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia. Liver Transpl. 2008;14(2):210–3.
Park JH, Cha SH, Han JK, Han MC. Intrahepatic portosystemic venous shunt. AJR Am J Roentgenol. 1990;155(3):527–8.
Morgan G, Superina R. Congenital absence of the portal vein: two cases and a proposed classification system for portasystemic vascular anomalies. J Pediatr Surg. 1994;29(9):1239–41.
Kondo F. Benign nodular hepatocellular lesions caused by abnormal hepatic circulation: etiological analysis and introduction of a new concept. J Gastroenterol Hepatol. 2001;16(12):1319–28.
Barton 3rd JW, Keller MS. Liver transplantation for hepatoblastoma in a child with congenital absence of the portal vein. Pediatr Radiol. 1989;20(1–2):113–4.
Pichon N, Maisonnette F, Pichon-Lefievre F, Valleix D, Pillegand B. Hepatocarcinoma with congenital agenesis of the portal vein. Jpn J Clin Oncol. 2003;33(6):314–6.
Yagi H, Takada Y, Fujimoto Y, Ogura Y, Kozaki K, Ueda M, et al. Successful surgical ligation under intraoperative portal vein pressure monitoring of a large portosystemic shunt presenting as an intrapulmonary shunt: report of a case. Surg Today. 2004;34(12):1049–52.
Gillespie MJ, Golden A, Sivarajan VB, Rome JJ. Transcatheter closure of patent ductus venosus with the Amplatzer vascular plug in twin brothers. Pediatr Cardiol. 2006;27(1):142–5.
Ohnishi Y, Ueda M, Doi H, Kasahara M, Haga H, Kamei H, et al. Successful liver transplantation for congenital absence of the portal vein complicated by intrapulmonary shunt and brain abscess. J Pediatr Surg. 2005;40(5):e1–3.
Franchi-Abella S, Branchereau S, Lambert V, Fabre M, Steimberg C, Losay J, et al. Complications of congenital portosystemic shunts in children: therapeutic options and outcomes. J Pediatr Gastroenterol Nutr. 2010;51(3):322–30.
Mulliken JB, Glowacki J. Classification of pediatric vascular lesions. Plast Reconstr Surg. 1982;70(1):120–1.
Dickie B, Dasgupta R, Nair R, Alonso MH, Ryckman FC, Tiao GM, et al. Spectrum of hepatic hemangiomas: management and outcome. J Pediatr Surg. 2009;44(1):125–33.
Frieden IJ, Haggstrom AN, Drolet BA, Mancini AJ, Friedlander SF, Boon L, et al. Infantile hemangiomas: current knowledge, future directions. Proceedings of a research workshop on infantile hemangiomas, April 7–9, 2005, Bethesda, Maryland, USA. Pediatr Dermatol. 2005;22(5):383–406.
Christison-Lagay ER, Burrows PE, Alomari A, Dubois J, Kozakewich HP, Lane TS, et al. Hepatic hemangiomas: subtype classification and development of a clinical practice algorithm and registry. J Pediatr Surg. 2007;42(1):62–7; discussion 7–8.
Hernandez F, Navarro M, Encinas JL, Lopez Gutierrez JC, Lopez Santamaria M, Leal N, et al. The role of GLUT1 immunostaining in the diagnosis and classification of liver vascular tumors in children. J Pediatr Surg. 2005;40(5):801–4.
Kulungowski AM, Alomari AI, Chawla A, Christison-Lagay ER, Fishman SJ. Lessons from a liver hemangioma registry: subtype classification. J Pediatr Surg. 2012;47(1):165–70.
Behr GG, Fishman SJ, Caty MG, Kulungowski AM, Paltiel HJ, Alomari AI. Hepatic mesenchymal hamartoma and infantile hemangioma: a rare association. J Pediatr Surg. 2012;47(3):448–52.
Huang SA, Tu HM, Harney JW, Venihaki M, Butte AJ, Kozakewich HP, et al. Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas. N Engl J Med. 2000;343(3):185–9.
Nord KM, Kandel J, Lefkowitch JH, Lobritto SJ, Morel KD, North PE, et al. Multiple cutaneous infantile hemangiomas associated with hepatic angiosarcoma: case report and review of the literature. Pediatrics. 2006;118(3):e907–13.
Leaute-Labreze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taieb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;24:2649–51.
Mhanna A, Franklin WH, Mancini AJ. Hepatic infantile hemangiomas treated with oral propranolol – a case series. Pediatr Dermatol. 2011;28(1):39–45.
Sans V, de la Roque ED, Berge J, Grenier N, Boralevi F, Mazereeuw-Hautier J, et al. Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics. 2009;124(3):e423–31.
Mazereeuw-Hautier J, Hoeger PH, Benlahrech S, Ammour A, Broue P, Vial J, et al. Efficacy of propranolol in hepatic infantile hemangiomas with diffuse neonatal hemangiomatosis. J Pediatr. 2010;157(2):340–2.
Geramizadeh B, Safari A, Bahador A, Nikeghbalian S, Salahi H, Kazemi K, et al. Hepatic angiosarcoma of childhood: a case report and review of literature. J Pediatr Surg. 2011;46(1):e9–11.
Awan S, Davenport M, Portmann B, Howard ER. Angiosarcoma of the liver in children. J Pediatr Surg. 1996;31(12):1729–32.
Chung EM, Lattin Jr GE, Cube R, Lewis RB, Marichal-Hernandez C, Shawhan R, et al. From the archives of the AFIP: pediatric liver masses: radiologic-pathologic correlation. Part 2. Malignant tumors. Radiographics. 2011;31(2):483–507.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Loverdos, I., Ling, S.C. (2014). Vascular Liver Disease. In: Murray, K., Horslen, S. (eds) Diseases of the Liver in Children. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-9005-0_21
Download citation
DOI: https://doi.org/10.1007/978-1-4614-9005-0_21
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-9004-3
Online ISBN: 978-1-4614-9005-0
eBook Packages: MedicineMedicine (R0)